TP53 and neoplasm: Recent studies have reported that specific gene alterations, such as TP53 (Sun et al., 2020), KRAS (Hamarsheh et al., 2020), EGFR (Chen et al., 2015), and STK11 (Mazzaschi et al., 2021) have an important role in the regulation of the tumor immune microenvironment (TIME) and served as biomarkers to tumor therapeutics (Lee et al., 2017; Krishnamurthy et al., 2021).